Patents by Inventor Claudie Namane

Claudie Namane has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10077237
    Abstract: The present invention relates to compounds corresponding to formula (I). Process for the preparation thereof and therapeutic use thereof. The compounds are modulators of the activity of AMP-activated protein kinase (AMPK) and are useful for treating e.g. diabetes and obesity.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 18, 2018
    Assignee: Sanofi
    Inventors: Eykmar Fett, Patrick Mougenot, Claudie Namane, Eric Nicolai, Olivier Venier
  • Publication number: 20160311770
    Abstract: The present invention relates to compounds corresponding to formula (I). Process for the preparation thereof and therapeutic use thereof. The compounds are modulators of the activity of AMP-activated protein kinase (AMPK) and are useful for treating e.g. diabetes and obesity.
    Type: Application
    Filed: December 19, 2013
    Publication date: October 27, 2016
    Inventors: Eykmar Fett, Patrick Mougenot, Claudie Namane, Eric Nicolai, Olivier Venier
  • Patent number: 8546391
    Abstract: The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: October 1, 2013
    Assignee: Sanofi
    Inventors: Eykmar Fett, Patrick Mougenot, Claudie Namane, Eric Nicolai, Christophe Philippo
  • Patent number: 8530473
    Abstract: The invention relates to a compound of the general formula (I), as defined herein which is useful in modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are useful for treating pathologies in which such modulation is beneficial, as in the case of metabolic syndrome or of noninsulin-dependent type 2 diabetes. The invention also relates to pharmaceutical preparations containing such a compound, processes for preparing and intermediates useful in the preparation of a such a compound.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: September 10, 2013
    Assignee: Sanofi
    Inventors: Claudie Namane, Eric Nicolai, Francois Pacquet, Cecile Pascal, Olivier Venier
  • Patent number: 8530657
    Abstract: The present invention relates to tetrahydroquinoxaline urea derivatives of formula (I) as defined herein, and, to their preparation and to their therapeutic application.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: September 10, 2013
    Assignee: Sanofi
    Inventors: Alain Jean Braun, Olivier Crespin, Claudie Namane, Eric Nicolai, Francois Pacquet, Cecile Pascal, Christophe Philippo, Olivier Venier
  • Publication number: 20120245148
    Abstract: The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 27, 2012
    Applicant: SANOFI
    Inventors: Alain Jean Braun, Olivier Crespin, Claudie Namane, Eric Nicolai, Francois Pacquet, Cecile Pascal, Christophe Philippo, Olivier Venier
  • Patent number: 8211892
    Abstract: The present invention relates to tetrahydroquinoxaline urea derivatives of Formula (I): as disclosed herein, to their preparation and to their therapeutic application.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: July 3, 2012
    Assignee: Sanofi-Aventis
    Inventors: Alain Jean Braun, Olivier Crespin, Claudie Namane, Eric Nicolai, Francois Pacquet, Cecile Pascal, Christophe Philippo, Olivier Venier
  • Publication number: 20120135958
    Abstract: The invention relates to compounds of formula (I), where: A is a bond, an oxygen, or an —CH2— group; Ar1 is a phenyl or heteroaryl group; Ar2 is a phenyl, heteroaryl, or heterocycloalkyl group; R1a,b,c and R2a,b,c are hydrogen or halogen, or an alkyl, cycloalkyl, or lkyl-cycloalkyl group optionally, substituted by one or more halogen atoms, or a —OR5 (hydroxy or alkoxy), hydroxy-alkyl, alkoxy-alkyl, alkoxy-alkoxy, halogenoalkyl, —O-halogenoalkyl, oxo, —CO-alkyl, —CO-alkyl-NR6R7, —CO-halogenoalkyl, —COOR5, alkyl-COOR5, —O-alkyl-COOR5, —SO2-alkyl, —SO2-cycloalkyl, —SO2-alkyl-cycloalkyl, —SO2-alkyl-OR5, —SO2-alkyl-COOR5, —SO2-alkyl-NR6R7, —SO2-halogenoalkyl, alkyl-SO2-alkyl, —SO2—NR6R7, —SO2-alkyl-O-alkyl-OR5, —CONR6R7, -alkyl-CONR6R7, or -alkyl-NR6R7 group, or further R1a, R1b, and R1c are bonded to R2a, R2b, R2c, respectively, and to the carbon atom having same, and are -alkyl-O—; R3 is a hydrogen atom or an alkyl group; R4 is a hydrogen or halogen atom or a cyano, —OR5, hydroxyalkyl, —COOR5, —NR6R7, ONR6R7, —
    Type: Application
    Filed: July 23, 2010
    Publication date: May 31, 2012
    Applicant: SANOFI
    Inventors: Claudie Namane, Eric Nicolai, Francois Pacquet, Cecile Pascal, Olivier Venier
  • Publication number: 20120040984
    Abstract: The invention relates to compounds of the formula (I) either (i) in the state of a base or an acid addition salt, or (ii) in the state of an acid or a base addition salt, as well as to a method for preparing same and to the therapeutic applications thereof.
    Type: Application
    Filed: January 27, 2010
    Publication date: February 16, 2012
    Applicant: SANOFI
    Inventors: Eykmar Fett, Patrick Mougenot, Claudie Namane, Eric Nicolai, Christophe Philippo
  • Patent number: 7947834
    Abstract: The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b and R4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11?-HSD1 is involved.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: May 24, 2011
    Assignee: Sanofi-Aventis
    Inventors: Alain Braun, Patrick Mougenot, Claudie Namane, Eric Nicolai, Francois Pacquet, Christophe Philippo, Olivier Venier, Olivier Crespin, Cecile Pascal, Michel Aletru, Stefan Gussregen
  • Publication number: 20110059964
    Abstract: The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.
    Type: Application
    Filed: February 3, 2010
    Publication date: March 10, 2011
    Applicant: sanofi-aventis
    Inventors: Michel Aletru, Peter Aranyi, Maria Balogh, Sandor Batori, Judit Bence, Philippe Bovy, Zoltan Kapui, Endre Mikus, Claudie Namane, Christophe Philippo, Tibor Szabo, Zsuzsanna Tomoskozi, Katalin Urban-Szabo
  • Patent number: 7897773
    Abstract: The present invention is related to a compound of formula (I) wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R4, p, r and are as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1).
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: March 1, 2011
    Assignee: Sanofi-Aventis
    Inventors: Michel Aletru, Alain Jean Braun, Claudie Namane, Olivier Venier, Christophe Philippo, Patrick Mougenot, Eric Nicolai, Stefan Gussregen
  • Publication number: 20110009391
    Abstract: The present invention relates to tetrahydroquinoxaline urea derivatives, to their preparation and to their therapeutic application.
    Type: Application
    Filed: July 26, 2010
    Publication date: January 13, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Alain Jean BRAUN, Olivier CRESPIN, Claudie NAMANE, Eric NICOLAI, Francois PACQUET, Cecile PASCAL, Christophe PHILIPPO, Olivier VENIER
  • Publication number: 20100324084
    Abstract: The present invention is related to a compound of formula (I) wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R4, p, r and are as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1).
    Type: Application
    Filed: August 30, 2010
    Publication date: December 23, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Michel ALETRU, Alain Jean BRAUN, Claudie NAMANE, Olivier VENIER, Christophe PHILIPPO, Patrick MOUGENOT, Eric NICOLAI, Stefan GUSSREGEN
  • Publication number: 20100298377
    Abstract: This disclosure relates to compounds of formula (I): wherein R1, R2, R3, R4, E, and n1 are as defined in the disclosure, to compositions containing them, to processes for preparing them, and the use thereof.
    Type: Application
    Filed: December 11, 2009
    Publication date: November 25, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Michel ALETRU, Dominique DAMOUR, Patrick MOUGENOT, Frederico NARDI, Patrick NEMECEK, Christophe PHILIPPO, Catherine MONSEAU, Claudie NAMANE
  • Publication number: 20100240580
    Abstract: The invention relates to azoloarine derivatives of formula I wherein R, A, B, D, Y, X, M and W are as defined herein, and their physiologically tolerated salts.
    Type: Application
    Filed: February 18, 2010
    Publication date: September 23, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard ZOLLER, Marc Dietrich VOSS, Hans MATTER, Andreas HERLING, Christophe Philippo, Claudie NAMANE, Juan-Antonio SANCHEZ-ARIAS
  • Patent number: 7659298
    Abstract: The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: February 9, 2010
    Assignee: sanofi-aventis
    Inventors: Michel Aletru, Peter Aranyi, Maria Balogh, Sandor Batori, Judit Bence, Philippe Bovy, Zoltan Kapui, Endre Mikus, Claudie Namane, Christophe Philippo, Tibor Szabo, Zsuzsanna Tomoskozi, Katalin Urban-Szabo
  • Publication number: 20090176775
    Abstract: The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b and R4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11?-HSD1 is involved.
    Type: Application
    Filed: December 18, 2008
    Publication date: July 9, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Alain BRAUN, Patrick MOUGENOT, Claudie NAMANE, Eric NICOLAI, Francois PACQUET, Christophe PHILIPPO, Olivier VENIER, Olivier CRESPIN, Cecile PASCAL, Michel ALETRU, Stefan GUSSREGEN
  • Publication number: 20090170894
    Abstract: The present invention is related to a compound of formula (I) wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R4, p, r and are as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1).
    Type: Application
    Filed: December 11, 2008
    Publication date: July 2, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Michel ALETRU, Alain Jean BRAUN, Claudie NAMANE, Olivier VENIER, Christophe PHILIPPO, Patrick MOUGENOT, Eric NICOLAI, Stefan GUSSREGEN
  • Publication number: 20070021459
    Abstract: The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.
    Type: Application
    Filed: June 21, 2006
    Publication date: January 25, 2007
    Applicant: SANOFI-AVENTIS
    Inventors: Michel ALETRU, Peter ARANYI, Maria BALOGH, Sandor BATORI, Judit BENCE, Philippe BOVY, Zoltan KAPUI, Endre MIKUS, Claudie NAMANE, Christophe PHILIPPO, Tibor SZABO, Zsuzsanna TOMOSKOZI, Katalin URBAN-SZABO